Dare Bioscience is a clinical-stage biopharmaceutical company. Co. identifies, acquires and develops a portfolio of therapies that expand treatment options and improve outcomes for women in the areas of contraception, fertility, and sexual and vaginal health. Co. has three product candidates: DARE-BV1, a bioadhesive hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis; Ovaprene®, a hormone-free, monthly vaginal contraceptive; and Sildenafil Cream, a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The DARE stock yearly return is shown above.
The yearly return on the DARE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2015 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the DARE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|